Design of FREESIA-3, a phase 3 open-label RCT randomising pregnant individuals at risk of FNAIT 4:1 to weekly nipocalimab or IVIG plus prednisone; primary endpoint is death, severe bleeding or platelet count <30 x10^9/L in the fetus/neonate. No results yet.
RCT
Bussel et al. Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia